Shares of TG Therapeutics Inc. (NASDAQ:TGTX) fell 5.1% during trading on Tuesday . The company traded as low as $5.64 and last traded at $5.64, with a volume of 163,823 shares. The stock had previously closed at $5.94.

A number of research firms recently commented on TGTX. Brean Capital reissued a “buy” rating on shares of TG Therapeutics in a report on Tuesday, May 31st. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a report on Wednesday, May 4th. SunTrust Banks Inc. started coverage on shares of TG Therapeutics in a report on Friday, May 27th. They issued a “buy” rating and a $18.00 price target on the stock. Zacks Investment Research downgraded shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a report on Thursday, June 9th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $22.33.

The stock’s market cap is $304.45 million. The stock’s 50-day moving average is $6.71 and its 200 day moving average is $8.22.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.08. On average, analysts forecast that TG Therapeutics Inc. will post ($1.15) EPS for the current fiscal year.

A hedge fund recently raised its stake in TG Therapeutics stock. New York State Common Retirement Fund boosted its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 as of its most recent filing with the SEC.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.